Rational design and development of novel NAE inhibitors for the treatment of pancreatic cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rational design and development of novel NAE inhibitors for the treatment of pancreatic cancer

Published:2023-01-12 Issue:3 Volume:32 Page:442-474
ISSN:1054-2523
Container-title:Medicinal Chemistry Research
language:en
Short-container-title:Med Chem Res

Author:

Lu Cheng,Lu Peng,Gong Lei,Zhu Li-Juan,An Yuanyuan,Wang Yubin

Publisher

Springer Science and Business Media LLC

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics

Link

https://link.springer.com/content/pdf/10.1007/s00044-022-02979-8.pdf

Reference39 articles.

1. Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin. 2020;70:375–403. https://doi.org/10.3322/caac.21626.

2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21. https://doi.org/10.1158/0008-5472.CAN-14-0155.

3. He J, Blair AB, Groot VP, Javed AA, Burkhart RA, Gemenetzis G, Hruban RH, Waters KM, Poling J, Zheng L, Laheru D, Herman JM, Makary MA, Weiss MJ, Cameron JL, Wolfgang CL. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer. Ann Surg. 2018;268:1–8. https://doi.org/10.1097/SLA.0000000000002672.

4. Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ. 2005;12:1191–7. https://doi.org/10.1038/sj.cdd.4401702.

5. Mocciaro A, Rape M. Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control. J Cell Sci. 2012;125:255–63. https://doi.org/10.1242/jcs.091199.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current scenario of fused pyrimidines with in vivo anticancer therapeutic potential;Archiv der Pharmazie;2024-05-16

2. Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions;Journal of Hematology & Oncology;2023-07-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3